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SUMMARY
The archaeal enzyme geranylgeranyl reductase (GGR) catalyzes hydrogenation of
carbon-carbon double bonds to produce the saturated alkyl chains of the organism’s
unusual isoprenoid-derived cell membrane. Enzymatic reduction of isoprenoid double
bonds is of considerable interest both to natural products researchers and to synthetic
biologists interested in the microbial production of isoprenoid drug or biofuel molecules.
Here we present crystal structures of GGR from Sulfolobus acidocaldarius, including the
structure of GGR bound to geranylgeranyl pyrophosphate (GGPP). The structures are
presented alongside activity data that depict the sequential reduction of GGPP to
H6GGPP via the intermediates H2GGPP and H4GGPP. We then modified the enzyme to
generate sequence variants that display increased rates of H6GGPP production or are able
to halt the extent of reduction at H2GGPP and H4GGPP. Crystal structures of these
variants not only reveal the structural bases for their altered activities; they also shed light
onto the catalytic mechanism employed.
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INTRODUCTION
Isoprenoids, also called terpenes and terpenoids, form a large and structurally diverse
class of natural products that display a multitude of biological functions. Isoprenoids are
also a major target in synthetic biology for the microbial production of biofuels,
medicines, and other commodity chemicals, such as the anti-malarial drug precursor
artemisinic acid (Ro et al., 2006), the taxol precursor taxadiene (Ajikumar et al., 2010),
the biodiesel precursors farnesene and bisabolene (Peralta-Yahya et al., 2011; Renninger
and McPhee, 2008), and the carotenoid lycopene (Alper et al., 2005; Farmer and Liao,
2000), which have all been produced in engineered microbes. All isoprenoids are
constructed from the isomeric five-carbon (C5) building blocks isopentenyl
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which are generated by
the mevalonate pathway or the 1-deoxy-D-xylulose 5-phosphate (DXP) pathway. IPP and
DMAPP are first condensed by prenyltransferases to form isoprenoid intermediates of
varying chain lengths: geranyl pyrophosphate (GPP, C10), farnesyl pyrophosphate (FPP,
C15), or geranylgeranyl pyrophosphate (GGPP, C20). Dedicated terpene synthases then
convert these intermediates into monoterpene (C10), sesquiterpene (C15), or diterpene
(C20) products using carbocation-based structural rearrangements, which use the double
bonds of GPP, FPP, and GGPP as nucleophiles to cyclize, adjust, and rearrange the
carbon skeleton. Terpene synthases are thus primarily responsible for the incredible
structural diversity of isoprenoid products.
Isoprenoids also form the major component of membrane phospholipids in
archaea. Unlike bacterial or eukaryotic membranes, which are primarily composed of
fatty acyl chains linked to phosphoglycerol by ester bonds, archaeal membranes are
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composed of isoprenoid-derived chains linked to phosphoglycerol by ether bonds. Here,
two geranylgeranyl chains from GGPP are first tethered to phosphoglycerol in the
molecule 2,3-di-O-geranylgeranylglyceryl phosphate (DGGGP). Next, the enzyme
geranylgeranyl reductase (GGR) performs the remarkable sixteen-electron reduction of
all DGGGP double bonds to produce saturated alkyl chains using flavin adenine
dinucleotide (FAD) as a cofactor. Interestingly, prior studies have shown that GGR from
Sulfolobus acidocaldarius (SaGGR) is able to reduce three out of the four double bonds
of the non-native substrate GGPP to produce the hexahydro-product, H6GGPP (Sato et al.,
2008). Although GGR from Thermoplasma acidophilum (TaGGR) can utilize NADPH as
a direct electron source (Nishimura and Eguchi, 2006), SaGGR cannot directly use
NADPH or NADH (Sato et al., 2008), and neither its ultimate in vivo source of electrons
nor any potential redox protein partners are currently known. In addition, crystal
structures of SaGGR and TaGGR have been previously determined (Sasaki et al., 2011;
Xu et al., 2010). Although SaGGR was co-crystallized with 1.0 mM GGPP, the electron
density was discontinuous and inconsistent with GGPP; instead, n-nonane and
pyrophosphate were modeled (Sasaki et al., 2011).
In addition to being of considerable biological interest due to its key role in
archaeal membrane biosynthesis, GGR also holds great promise for isoprenoid
production in engineered microbes, as its isoprenoid double bond reduction activity
would allow for greater tailoring of the final product. Here, reduction of isoprenoid
double bonds would decrease the reactivity and sensitivity to oxidation of the target
compound, in addition to altering its physicochemical properties. Such features are
especially beneficial for isoprenoid-based biofuels; in fact, microbially produced
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farnesene and bisabolene must first be hydrogenated to farnesane and bisabolane,
respectively, to become practical biodiesel alternatives (Peralta-Yahya et al., 2011;
Renninger and McPhee, 2008). Further, in vivo enzymatic hydrogenation has several
advantages over chemical hydrogenation. First, the capital cost of chemical
hydrogenation would be eliminated by simply using a strain that expresses a requisite
hydrogenation enzyme. In addition, in vivo hydrogenation would be valuable in host
organisms that use the mevalonate pathway in anaerobic fermentation, where redox
balance becomes a serious issue. Here, GGR could play an important role in consuming
excess reducing equivalents and regenerating oxidized NAD(P)+. Enzymatic reduction of
double bonds within the biosynthetic pathway also raises the possibility of using an
engineered enzyme that could selectively reduce specific double bonds, as opposed to
chemical hydrogenation of an isolated final product that would likely reduce all double
bonds. Despite its potential, however, the use of GGR in synthetic biology for the
reduction of isoprenoids has remained largely unexplored and unstudied, as GGR not
only awaits further biochemical and structural characterization, but practical GGR
enzymes must also be identified or engineered.
Here, we present the structure of SaGGR bound with GGPP, along with activity
data on GGPP reduction using a new enzymatic assay based on mass spectrometry. Using
these results, we performed structure-guided design of SaGGR to alter the reaction rate
and to tailor the extent of GGPP reduction. We generated SaGGR variants that exhibit
increased rates of H6GGPP production and also identified additional SaGGR variants that
are capable of halting GGPP reduction at the dihydro-product, H2GGPP, and at the
tetrahydro-product, H4GGPP. Crystal structures of these SaGGR variants bound to GGPP
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reveal the structural bases for their altered activities and further illuminate the catalytic
mechanism of GGR, an enzyme of both biological interest and of potential utility in the
microbial production of isoprenoid compounds.

RESULTS AND DISCUSSION
Structure and activity of wild-type SaGGR
Crystal structures of SaGGR were determined to high resolution bound to
phosphatidylglycerol (PG) and to GGPP. During the preparation of this manuscript, the
structure of SaGGR in complex with a non-physiological ligand was published (Sasaki et
al., 2011), which described the overall structure of SaGGR in detail. Briefly, SaGGR is a
monomer composed of two functional domains: an FAD-binding Rossmann–type fold
domain (residues 1–74) and a ligand–binding domain (residues 75–453) (Figure 1). The
overall structure closely resembles TaGGR (Xu et al., 2010) with an r.m.s.d of 1.5 Å over
350 residues. SaGGR possesses an additional 60 amino acids at the C-terminus that
TaGGR does not. This region is !-helical in nature and is contiguous with the ligandbinding domain; it does not clearly form a domain distinct from the ligand-binding
domain.
Alhough our crystals were prepared without substrate, additional density was
observed in the active site (Figure S1A). Lipid analysis later revealed this to be PG,
which, while not a GGR substrate, has a similar structure to the native substrate DGGGP
(Figure S1B), and it is likely that the membrane lipid remained bound during purification.
The two chains of PG bind in separate cavities (Figure S1A), and only one chain, which
interacts with the FAD, appears to be bound in a catalytically relevant manner. The
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chains are separated by Y215 and a loop region (290-301). The phosphate in the lipid
head group forms salt bridge interactions with H55 and H297 and hydrogen bonds with
Y340 and N294.
We also co-crystallized SaGGR with GGPP (Figures 1 and 2A). Unexpectedly,
electron density was resolved for three separate molecules of GGPP (Figure S2A).
Similar to PG, only one GGPP molecule (GGPP1) appears to be bound in a catalytically
competent manner. The hydrophobic chain from the second GGPP molecule (GGPP2) is
bound in a manner similar to the second chain from PG. The third GGPP molecule
(GGPP3) binds SaGGR alongside GGPP2 within the same cavity. Although electron
density was clear for all GGPP alkyl chains, disorder was observed in the pyrophosphate
head groups of some GGPP binding sites. Only the model for GGPP1 includes both
phosphate groups of the pyrophosphate moiety. The model for GGPP2 contains a single
phosphate, and GGPP3 is modeled without any phosphates, and it is possible that GGPP
became dephosphorylated during the course of crystallization. Therefore, a mixture of
substrates with different degrees of phosphorylation may be present and only the
phosphates that could be confidently fit into the electron density were included in the
model. However, to avoid confusion all GGPP-based ligands will be referred to as GGPP.
The pyrophosphate moiety of GGPP1 binds SaGGR in a completely different
manner than the phosphate in PG. The "-phosphate forms a hydrogen bond with the
backbone carbonyl of N90, while the phosphate of GGPP2 shows similar binding
interactions as the phosphate from PG: salt bridges are formed between the
pyrophosphate moiety and H55, H297, and K343 and hydrogen bonds occur with Y340
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and N294 (Figure 2A). In all three GGPP molecules, the alkyl chains are bound by
hydrophobic residues of the protein.
In the bound GGPP1 molecule that represents reactive GGPP binding, the terminal
double bond at the opposite end from the pyrophosphate group, the #14 double bond, sits
directly facing the N5 position of FAD (3.1 Å) from which it accepts a hydride for its
reduction. Interestingly, the GGPP methyl group adjacent this double bond is located in
the space formed between the conserved residues F219 and W217 (Figure 2B). Because
all other geranylgeranyl double bonds of the native DGGGP substrate must also be
reduced by FAD in the reaction cycle, all double bonds would be positioned in a similar
manner, with their adjacent, branching methyl groups wedged between F219 and W217.
In this way, these two residues are involved in properly orienting the substrate in order to
present the double bond to FADH2 for reduction.
Our activity studies of wild-type (WT) SaGGR with GGPP reveal a six-electron
reduction of GGPP to H6GGPP, via the intermediates H2GGPP and H4GGPP, with an
optimal temperature of approximately 50°C and an optimal pH of approximately 5.5
(Figure S3). In the reaction, GGPP (m/z: 449.2) is reduced first to H2GGPP (m/z: 451.2),
which is observed only initially and in low levels (Figure 3A and Figure S4).
Subsequently, a more significant build up of H4GGPP (m/z: 453.2) occurs, attaining a
maximum accumulation after approximately 3 min. This H4GGPP intermediate is then
consumed with concomitant formation of the product, H6GGPP (m/z: 455.2). The fully
reduced form, H8GGPP (expected m/z: 457.2), was not detected (Figure S4). These
findings are consistent with prior SaGGR results, which also identified H6GGPP as the
product with the greatest degree of GGPP reduction (Sato et al., 2008). Time course
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experiments yield a maximal apparent rate (vapp) of H6GGPP formation of 12 ± 2 µM
min-1 and an apparent rate constant (kapp) for H6GGPP of 0.40 ± 0.05 min-1 (Table 2).
Another useful metric to assess the rate of reaction is the time required to reach 50%
maximal conversion (t50) of GGPP to H6GGPP, which was 6.3 min.

Engineered GGR variants with altered activity
Using our crystal structure of GGPP-bound WT SaGGR, we designed mutant enzymes
with the goal of altering enzyme activity. We then determined crystal structures for
engineered variants with improved activity or those that may provide insight into the
enzyme mechanism. One objective was to engineer SaGGR to fully reduce the non-native
GGPP substrate, as reduction to H8GGPP had not been observed in the WT enzyme.
Because the crystal structure depicted the site of the terminal, #14 GGPP double bond
poised for reduction by FAD (Figure 2B), and because our activity studies showed that
three of the four double bonds are reduced, we speculated that the remaining, unreduced
double bond was the double bond closest to the pyrophosphate, the #2 double bond. This
judgment was also reached in prior SaGGR experiments with GGPP (Sato et al., 2008).
Therefore, we targeted the largely hydrophobic residues lining the GGPP-binding
channel for mutation to polar or positively charged residues, with the aim of bringing the
pyrophosphate moiety deeper into the active site. We also mutated these residues to those
with smaller side chains in order to better accommodate the pyrophosphate head group.
Another objective was to inhibit unproductive binding of GGPP to the auxiliary binding
sites observed in the crystal structure as GGPP2 and GGPP3 (Figure 2A). Here, we
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mutated residues pointed towards these binding channels to bulkier hydrophobic residues
in order to sterically hinder non-catalytic GGPP binding.
Of the >30 SaGGR variants tested, none fully reduced GGPP to H8GGPP.
However, several mutants displayed interesting activity profiles that significantly differed
from WT SaGGR. Two mutants, I206F and L377H, exhibited faster overall reduction of
GGPP to H6GGPP compared to WT SaGGR (Figure 3F). Time course experiments gave
vapp of H6GGPP for I206F and L377H mutants of 16 ± 4 and 28 ± 11 µM min-1,
respectively, kapp of 0.53 ± 0.14 and 0.94 ± 0.36 min-1, respectively, and t50 of 5.0 and 3.7
min, respectively (Table 2). As with the wild-type enzyme, the I206F and L377H mutants
reduce GGPP first by rapid formation and consumption of H2GGPP, followed by an
initial buildup of H4GGPP that precedes reduction to H6GGPP, the final product
(Figures 3B-3C, Figure S4).
The I206F mutation was intended to obstruct non-catalytic GGPP binding in the
GGPP2 and GGPP3-binding sites determined in the WT crystal structure. The structure of
this variant confirms that F206 partially occludes the second cavity (Figure 4A and
Figure S2B). Therefore, the catalytically inactive binding conformations are unavailable
to GGPP. Weak electron density was observed for the GGPP1 position. However, the
ligand could not be modeled with full confidence and was not included in the final
structure (Figure S2B).
For the L377H mutant, the WT SaGGR crystal structure shows L377 residing on
the enzyme’s surface, at the opening of the catalytic GGPP binding site and directly
adjacent the pyrophosphate head group. Mutation of this residue to histidine was intended
to stabilize GGPP binding in its catalytic binding site. Indeed, H377 of the mutant forms
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a salt bridge with the GGPP pyrophosphate (Figure 4B), thereby improving substrate
binding. Apart from its interaction with H377, GGPP binds to the L377H in the same
way as it binds to the WT enzyme, with the terminal, #14 double bond directly adjacent
the N5 of FAD (Figure 4B).
Interestingly, a double I206F/L377H mutant produced H6GGPP faster than either
of the single I206F or L377H mutants (Figure 4, Figure S4), with vapp, kapp, and t50 for
H6GGPP of 29 ± 3 µM min-1, 0.95 ± 0.09 min-1, and 2.6 min, respectively (Table 2).
Overall, the I206F/L377F mutant was the fastest SaGGR variant tested, generating
H6GGPP approximately 2.4-fold faster than the WT enzyme. The crystal structure of the
I206H/L377H double mutant correspondingly depicts the features of both I206F and
L377F single-mutant structures described above combined in the same structure, with
GGPP also bound with its #14 double bond directly adjacent the N5 of FAD. From these
data, it appears that the rate-enhancing effects of the individual mutations are additive.
On the other hand, another mutant, G91H, halts the reduction of GGPP at
H2GGPP (Figure 3D, Figure S4). After reaching maximal H2GGPP levels after
approximately 10 min, only a very small quantity of H2GGPP is reduced further to
H4GGPP or to H6GGPP (Figures 3D and 3F). This is in contrast to the H6GGPPproducing WT, I206F, L377H, and I206F/L377H enzymes discussed above, which do not
accumulate appreciable levels of H2GGPP at any point during the reaction. The G91H
mutant displays vapp, kapp, and t50 for H2GGPP of 25 ± 4 µM min-1, 0.83 ± 0.14 min-1, and
3.0 min, respectively (Table 2). Notably, the G91H t50 for H2GGPP is slightly greater
than the I206F/L377H t50 for H6GGPP, indicating that the fastest H6GGPP producer
performs three reductions of GGPP (from GGPP to H6GGPP) faster than G91H performs
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one reduction (from GGPP to H2GGPP). Interestingly, although mutation of both G91
and L377 to histidine gives completely different reactive outcomes, forming H2GGPP
and H6GGPP products, respectively, both residues in the WT SaGGR crystal structure are
located at a similar position on the surface of the enzyme, at the opening of the same
GGPP binding site. In fact, G91 and L377 sit directly across the opening from each other,
with the GGPP pyrophosphate group located in the center. Our crystal structure of the
G91H variant shows that, like H377 in the L377H mutant, H91 similarly forms a salt
bridge with the GGPP pyrophosphate (Figure 4C). However, unlike in the L377H
structure, GGPP in the G91H structure is bound in a different position, where the GGPP
substrate has slid farther into the protein cavity, placing the #6 double bond instead of the
#14 double bond directly adjacent N5 of FAD.
Going one reduction further than the G91H mutant, another SaGGR variant, the
F219L mutant, ceases GGPP reduction at H4GGPP without significant conversion to
H6GGPP (Figure 3E, Figure S4). Interestingly, F219 is a conserved residue that is
thought to serve a role in substrate binding as described above, where the GGPP methyl
group flanking the reduced double bond is wedged between F219 and the conserved
W217 in order to correctly orient the substrate double bond for reduction by FADH2.
Mutation of F219 to leucine was intended to provide more room in the substrate-binding
channel for the pyrophosphate head of GGPP to move farther into the active site without
compromising the hydrophobic environment. The crystal structure of the F219L mutant
confirms that this is the case (Figure 4D). In experiments with the F219L mutant, a small
buildup of H2GGPP is observed after the reaction is initiated, followed by the production
of H4GGPP, with vapp, kapp, and t50 for H4GGPP of 23 ± 5 µM min-1, 0.78 ± 0.15 min-1,
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and 3.0 min, respectively (Table 2), without significant reduction to H6GGPP (Figure 3F).
It is possible that the increased size of the active site cavity no longer provides sufficient
van der Waals interactions for efficient binding and further reduction of the substrate.
Using simple mutations derived from structure-guided design, we have enhanced
and expanded the catalytic repertoire of SaGGR activity towards a non-native substrate,
GGPP. Three mutants (I206F, L377H, and I206F/L377H) exhibit faster production of
H6GGPP than the WT, increasing the overall rate of product formation by up to 2.4-fold.
Two other mutants selectively arrest the progression of GGPP reduction at different
intermediate stages, with G91H producing H2GGPP and F219L producing H4GGPP at
rates comparable to H6GGPP formation in the fastest H6GGPP-producing mutants. These
mutants provide customized degrees of hydrogenation for the key isoprenoid intermediate
GGPP. Overall, these results highlight the power of structure-guided design in tailoring
the kinetic and reactive outcomes of enzymes through small changes in the protein
sequence.

Mechanistic implications
Our structures of engineered SaGGR variants not only reveal the structural bases for their
altered reactivities, they also help illuminate the enzymatic mechanism employed. As
these structures capture snapshots of the GGPP substrate at different stages during the
reaction, the mechanism by which GGR reduces successive double bonds of the same
substrate may be more deeply explored.
As discussed, the GGPP-bound crystal structures of the H6GGPP-producing
enzymes (WT and L377H GGR) show the GGPP #14 double bond directly adjacent the
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N5 position of the FAD cofactor. On the other hand, the structure of the G91H mutant,
which reduces just one double bond to form H2GGPP, shows that formation of the salt
bridge between H91 and the GGPP1 pyrophosphate now places the #6 double bond
adjacent N5 of FAD. These results suggest that the first double bond to be reduced is the
#6 double bond, while the #14 double bond is the last double bond to be reduced. Here,
through its interaction with the GGPP1 pyrophosphate, the G91H mutant obstructs
translocation of the H2GGPP intermediate to inhibit further reduction (Figure 4C). This
reduction sequence implies that the double bond between #6 and #14, the #10 double bond,
is the second to be reduced. As H8GGPP is not formed by any enzyme, these data suggest
that the #2 double bond is left intact, consistent with prior studies (Sato et al., 2008). In
all, our SaGGR structures indicate that GGR first reduces GGPP at the #6 double bond,
then at #10, and finally at #14 (Fig. S2C).
Interestingly, in the structure of the F219L mutant which performs two reductions
of GGPP to H4GGPP, GGPP1 is bound in the same manner as in the WT and L377H
structures, with the #14 double bond adjacent the N5 of FAD (Figure 4D). This
observation suggests that the F219L variant first reduces the #10 double bond before
reducing the #14 double bond, giving the GGPP1 position represented in the structure and
consistent with the order of reduction described above.
Although the order of double bond reduction is suggested by the structures, the
structures do not indicate whether GGR employs a processive mechanism or not, that is
whether the enzyme successively reduces the double bonds of a single substrate molecule
before moving on to the next, or whether H2GGPP or H4GGPP intermediates dissociate
from the enzyme before the final H6GGPP product is made. However, the mass
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spectrometry data indicate that the mechanism of H6GGPP formation is not processive, as
before H6GGPP is made, GGPP continues to be consumed to form H2GGPP and
H4GGPP, allowing a clear buildup of the intermediate H4GGPP. Therefore, H4GGPP
must dissociate from the enzyme, enabling the next molecule of GGPP to bind and be
reduced, before reduction of H4GGPP to H6GGPP proceeds. However, it is difficult to
determine whether the first two GGPP reductions, first to H2GGPP and then to H4GGPP,
are processive. On the one hand, a processive mechanism to H4GGPP appears to be
supported by the data, as no significant buildup of H2GGPP is observed. However, it is
also possible that the second reaction to form H4GGPP is sufficiently faster than the first
to allow rapid reduction of H2GGPP, making the first step rate-determining. Additional
studies may be performed to further explore the processivity of GGR reduction. Although
it is possible that the native reaction with DGGGP may not follow the same mechanism,
this is unlikely as the enzyme catalyzes the reduction of the same geranylgeranyl moiety
of both GGPP and DGGGP substrates.

Conclusions
The crystal structure of WT SaGGR bound with GGPP was determined, which
unexpectedly showed three binding sites for GGPP and revealed how the enzyme orients
double bonds to be reduced by the bound FAD cofactor. Structure-guided design of the
enzyme yielded SaGGR variants that enhanced the rate of H6GGPP product formation.
Interestingly, additional mutants were observed to arrest the degree of GGPP reduction at
H2GGPP and H4GGPP. Crystal structures of these variants reveal the structural bases for
their altered activities, in addition to providing insight into the SaGGR mechanism.
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With these GGR variants, the degree of GGPP reduction can be customized
enzymatically, a feature that is particularly useful in synthetic biology. As GGPP is a key
intermediate in the production of countless isoprenoid-derived products, including all
diterpenes, retinoids, and carotenoids, modified GGRs such as these may be used to tailor
the degree of hydrogenation and alter the isoprenoid product profile. Because terpene
synthases rely on double bonds at specific positions to rearrange the carbon skeleton, the
use of modified GGRs to selectively reduce specific GGPP double bonds can re-direct
the reactive outcome towards different products. In addition, it is useful that, as with the
WT enzyme, no SaGGR variants reduced the #2 double bond, as a double bond in this
position is necessary for providing the resonance-stabilized allylic carbocation in
subsequent reactions that involve removal of the pyrophosphate group; if the #2 double
bond were reduced, the resulting H8GGPP would be a dead-end product. As our
engineered enzymes exhibit altered product profiles, these studies pave the way for the
use of modified GGRs in the microbial production of tailored isoprenoid products.

EXPERIMENTAL PROCEDURES
Plasmid construction
A codon-optimized gene encoding SaGGR was synthesized (Genscript USA, Inc.) with
flanking Nde I and BamH I restriction sites. The gene cassettes were digested with Nde I
amd BamH I and ligated into pSKB3, a plasmid which confers kanamycin resistance and
encodes a TEV protease-cleavable N-terminal hexahistadine tag to aid in protein
purification. Mutant SaGGR constructs were made by standard oligonucleotide-directed
PCR mutagenesis using pSKB3-SaGGR as a template and the complementary
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oligonucleotides listed in Table S1 as primers. All constructs were verified by DNA
sequencing (Quintara Biosciences).

Protein overexpression and purification
Plasmids were transformed into Escherichia coli BLR(DE3) or Rosetta2(DE3)pLysS
cells for overexpression. Cells were grown in LB or TB medium supplemented with
50!µg/mL kanamycin, or 50!µg/mL kanamycin plus 34!µg/mL chloramphenicol in the
case of the Rosetta2(DE3)pLysS cells, at 37°C to an OD600 of 0.5-0.7, when the cultures
were transferred to 18°C. Overnight overexpression was then induced with 0.1-0.5 mM
isopropyl "-D-1-thiogalactopyranoside (IPTG). Cells were harvested by centrifugation at
5,000 $ g for 15 min at 4°C, flash-frozen in liquid nitrogen, and stored at -80°C until use.
Cells were thawed and resuspended in Lysis Buffer (20 mM NaH2PO4, pH 7.4,
200 mM NaCl, 20 mM imidazole), and phenylmethylsulfonyl fluoride (PMSF) and
Benzonase (EMD Millipore) were added at 0.5 mM and 5 U/mL concentrations,
respectively. Cell lysis was performed by sonication, and cell debris was pelleted by
centrifugation at 50,000 $ g for 30 min. Soluble extracts were incubated with Ni-NTA
resin for 1 h at 4°C and loaded onto a column. The flow-through was discarded and the
resin was washed with approximately 10 column volumes of Lysis Buffer containing
40 mM imidazole. Protein was eluted with Lysis Buffer containing 250 mM imidazole,
and yellow fractions representing FAD-bound GGR were collected and pooled. The
purified protein was buffer-exchanged into Lysis Buffer by either overnight dialysis or
cycles of protein concentration and dilution.
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To remove the hexahistidine tag, EDTA (0.5 mM), DTT (1 mM), and
hexahistidine-tagged TEV protease (approximately 1:100 molar ratio compared to GGR)
were added. Reactions were mixed and incubated overnight at room temperature. TEV
protease, cleaved hexahistidine tags, and any remaining uncleaved SaGGR were removed
by passing the solution through Ni-NTA resin pre-equilibrated with Lysis Buffer and
collecting the flow-through. Successful cleavage of the tag and the purity of SaGGR were
assessed by SDS-PAGE. The protein was then buffer exchanged into 20 mM NaH2PO4,
pH 7.4, using a Sephadex G-25 column (GE Healthcare) and concentrated to 7-10 mg/mL.
Final protein concentrations were determined by the Bradford method (Bradford, 1976)
and by the absorbance at 280 nm using a calculated extinction coefficient, !, of
82,100 M-1 cm-1. Protein samples were either used directly or aliquoted, flash frozen in
liquid nitrogen, and stored at -80°C until use.

Enzymatic assays
Reactions were performed at least in triplicate and contained 100 mM 2-(Nmorpholino)ethanesulfonic acid (MES) pH 5.5, 20 mM sodium dithionite, 200 µM FAD,
and 100 µM GGPP. Reaction mixtures were pre-heated to 50°C and initiated by the
addition of 30 µM purified SaGGR. The reactions were mixed and incubated at 50°C for
varying durations. Reactions were quenched and extracted with an equal volume of
n-butanol. In experiments that determined the pH optimum, 100 mM citric acid/sodium
citrate (pH 2.5-5.0), MES (pH 5.5-6.5), and NaH2PH4/Na2HPO4 (pH 7.0-8.0) were used
as reaction buffers in place of MES, pH 5.5. In experiments that determined the
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temperature optimum, reaction mixtures were pre-heated to varying temperatures on a
thermal cycler, and purified WT SaGGR was added to initiate the reaction.
To screen SaGGR variants for the extent of GGPP reduction, the organic phase
was analyzed by LC-MS. Reaction products were separated by HPLC (Agilent
Technologies) using a 2.1$150 mm ZIC-pHILIC column (EMD Millipore) and an
isocratic elution of 64% v/v acetonitrile and 36% v/v 50 mM ammonium acetate in water
at a flow rate of 0.15 mL/min at 40°C. The HPLC system was coupled to a triple
quadrupole mass spectrometer (Applied Biosystems). Electrospray ionization (ESI) was
conducted in the negative ion mode, and single ion monitoring (SIM) was used for the
detection of [M-H]- ions at approximately 449, 451, 453, and 455 m/z, representing
GGPP, H2GGPP, H4GGPP, and H6GGPP, respectively.
To quantify GGPP and its reactions products for WT SaGGR and select mutants,
the organic phase was analyzed by LC-TOF MS. Reaction products were separated by
HPLC using a ZIC-pHILIC column (Merck SeQuant, via The Nest Group, Inc., MA) and
an isocratic elution of 62% v/v acetonitrile and 37% 50 mM ammonium carbonate in
water at a flow rate of 0.2 mL/min at 40°C. The HPLC system was coupled to a time-offlight mass spectrometer (Agilent Technologies). ESI was conducted in the negative ion
mode, and MS experiments were carried out in full scan mode, at 0.86 spectra/s for the
detection of [M-H]- ions. The instrument was tuned for a range of 50-1700 m/z. Data
acquisition and processing were performed by the MassHunter software package.
Analytes were quantified using seven-point calibration curves (1.5625-100 µM GGPP)
whose R2 coefficients were >0.99.
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The total concentrations of all reaction products varied between samples, perhaps
due to differences in extraction efficiency. Therefore, instead of directly establishing
absolute concentrations for each product, relative concentrations were first determined
and as a percentage of the total products for each sample. Apparent reaction rates, vapp,
for each sample were thus determined initially in units of % min-1, which were then
converted to µM min-1 given the initial substrate concentration of 100 µM. The validity of
this unit conversion rests only on the assumption that GGPP, H2GGPP, H4GGPP, and
H6GGPP extract with approximately equal efficiencies, which we believe is reasonable.

Crystallization
Purified WT and mutant SaGGR were concentrated to ~10 mg/ml in a buffer containing
25 mM HEPES pH 7.4. Crystallization screening was carried out on a Phoenix robot (Art
Robbins Instruments, Sunnyvale, CA) using a sparse matrix screening method (Jancarik
and Kim, 1991). Proteins were crystallized by sitting-drop vapor diffusion in drops
containing a 1:1 ratio of protein solution and 0.1 M Tris pH 7.5, 10% PEG 3350 and 0.2
M L-proline. An additional 5 mM GGPP was added to the crystallization buffer to obtain
the ligand-bound crystals. Yellow crystals were observed within two days. For data
collection, crystals were flash frozen in liquid nitrogen from a solution containing mother
liquor and 10% glycerol.

X-ray data collection and structure determination
The X-ray diffraction data for SaGGR were collected at the Berkeley Center for
Structural Biology beam lines 8.2.1 and 8.2.2 of the Advanced Light Source at Lawrence
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Berkeley National Laboratory. Diffraction data were recorded using ADSC Q315R
detectors (Area Detector Systems Corporation, San Diego, CA). Processing of image data
was performed using the HKL2000 suite of programs (Otwinowski and Minor, 1997).
For the WT structure, phases were calculated by molecular replacement with the program
PHASER (McCoy et al., 2007), using the structure of TaGGR (PDB ID: 3OZ2) (Xu et al.,
2010) as a search model. Automated model building was conducted using Autobuild
(Terwilliger, 2003) from the PHENIX suite of programs (Adams et al., 2010) resulting in
a model that was 85% complete. Manual building using Coot (Emsley and Cowtan, 2004)
was alternated with reciprocal space refinement using PHENIX (Afonine et al., 2012).
Waters were automatically placed using PHENIX and manually added or deleted with
Coot according to peak height (>3.0 % in the Fo-Fc map) and the distance to a potential
hydrogen bonding partner (< 3.5 Å). TLS refinement (Winn et al., 2001) of 10 groups,
chosen by the TLSMD web server (Painter and Merritt, 2006), was used in later rounds
of refinement. All mutant structures were refined and built in the same manner as the WT
model. All data collection, phasing, and refinement statistics are summarized in Table 1.
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Figure 1. Overall fold of SaGGR. The structure of SaGGR was solved to high
resolution bound with GGPP (magenta). SaGGR is a monomer composed of two
functional domains, an FAD (yellow) binding Rossmann-type fold domain (residues 174) and a ligand–binding domain (residues 75-453). Protein in cyan ribbons and FAD (C
in yellow) and GGPP (C in magenta) shown in sticks, with O in red, N in blue, and P in
orange.
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Figure 2. Active site of SaGGR. (A) SaGGR was co-crystallized with GGPP. Electron
density was resolved for three separate molecules of GGPP (Figure S2). Like PG, only
one chain (GGPP1), appears to be bound in a catalytically competent manner, with its #14
double bond proximal to N5 of FAD. The hydrophobic chain from the second molecule
(GGPP2) is bound in a similar manner as the second chain from PG. The third molecule
(GGPP3) binds SaGGR alongside GGPP2 within the same cavity. (B) The SaGGR active
site showing the FAD isoalloxazine ring, the GGPP1 #14 double bond, and conserved
residues W217 and F219. FAD (C in yellow), GGPP (C in magenta), and protein residues
(C in cyan) shown in sticks, with O in red, N in blue, and P in orange.
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Figure 3. Distribution of WT and mutant SaGGR reaction products over time.
Reaction products for (A) WT, (B) I206F, (C) L377H, (D) G91H, and (E) F219L SaGGR.
(F) Time-dependent formation of H6GGPP from GGPP for WT and mutant SaGRR. WT,
I206F, L377H, and I206F/L377H SaGGR produce H6GGPP as the final product.
However, the primary products of the G91H and F219L mutants are H2GGPP and
H4GGPP, respectively. The apparent rate of GGPP reduction to H6GGPP was enhanced
in I206F, L377H, and I206F/L377H mutants compared to the WT.
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Figure 4. Active sites of engineered SaGGR variants. (A) The I206F mutant shows
increased activity compared to WT SaGGR. GGPP1 and GGPP2 are not present in this
structure but have been modeled in to demonstrate that F206 partially occludes the
second cavity. Therefore, this catalytically inactive binding conformation is unavailable
to GGPP. I206 from the WT structure (orange) has been overlaid with F206 to
demonstrate the steric hindrance caused by the introduction of a bulky phenylalanine. (B)
The L377H mutant shows improved activity over WT and I206F and reduces 3 of the 4
GGPP double bonds. H377 forms a salt bridge with the GGPP pyrophosphate. (C) The
G91H mutant reduces only one GGPP double bond. H91 forms a salt bridge with the
GGPP pyrophosphate, with the #6 double bond adjacent the N5 of FAD. (D) The F219L
mutant only reduces two GGPP double bonds. The mutation increases the size of the
active site cavity and may no longer provide sufficient van der Waals interactions for
efficient binding and reduction of substrate. FAD (C in yellow), GGPP (C in magenta),
and protein residues (C in cyan) shown in sticks, with O in red, N in blue, and P in orange.
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Table 1. X-ray data collection and refinement statistics.
PDB ID
Resolution (Å)
Space group
Unit cell (Å)

Total reflections
Unique reflections
Multiplicity
Completeness (%)
I/sigma(I)
R-sym
R-factor
R-free
RMS from ideal
geometry
Bonds (Å)
Angles (°)
Ramachandran
plot
Favored (%)
Outliers (%)
Clashscore

SaGGR

GGPP

G91H

I206F

L377H

F219L

I206F/L377H

4OPC
50 -1.4
(1.42 -1.4)
C121
a = 109.0
b = 65.3
c = 63.2
! = & = 90°
" = 92.0°

4OPU
50 – 2.70
(2.75 – 2.70)
P212121
a = 63.9
b = 82.0
c = 106.2
! = " = & = 90°

4OPL
50 – 2.48
(2.52-2.48)
P212121
a = 65.3
b = 78.9
c = 106.0
! = " = & = 90°

4OPG
50 – 2.07
(2.11-2.07)
P212121
a = 63.2
b = 81.7
c = 105.9
! = " = & = 90°

4OPI
50 – 2.24
(2.28-2.24)
P212121
a = 63.8
b = 83.0
c = 106.4
! = " = & = 90°

4OPT
50 – 2.60
(2.64-2.60)
P212121
a = 63.7
b = 82.2
c = 106.4
! = " = & = 90°

511159
83434
6.1 (4.5)
96.60 (82.40)
33.7 (1.92)
0.039 (0.506)
0.15
0.18

4OPD
50 - 1.83
(1.86 - 1.83)
P1
a = 63.1
b = 63.2
c = 65.1
! = 121.0°
" = 90.0°
& = 88.6°
272344
75985
3.6 (2.6)
97.30 (93.4)
11.1 (1.15)
0.107 (0.547)
0.15
0.19

153053
15943
9.6 (8.3)
98.7 (87.2)
17.8 (1.46)
0.122 (0.892)
0.21
0.25

181226
19915
9.1 (5.7)
97.4 (77.1)
28.5 (1.53)
0.103 (0.644)
0.26
0.29

328857
34256
9.6 (8.0)
100.0 (99.9)
27.7 (1.82)
0.075 (0.890)
0.19
0.21

186897
27895
6.7 (5.4)
99.3 (93.5)
23.0 (2.87)
0.068 (0.547)
0.19
0.23

121720
17900
6.8 (5.5)
98.0 (81.4)
15.3 (1.43)
0.110 (0.816)
0.19
0.22

0.006
1.1

0.007
1.064

0.002
0.723

0.002
0.564

0.002
0.612

0.002
0.716

0.002
0.575

99
0
1.98

98
0.2
3.83

98
0
4.22

98
0
2.91

98
0
1.9

98
0
1.91

97
0
2.47

Statistics for the highest-resolution shell are shown in parentheses.

Table 2. Kinetic data for wild-type SaGGR and its engineered mutants.
SaGGR variant

Product

vapp (µM min-1)

kapp (min-1)

t50 (min)

WT
H6GGPP
12 ± 2
0.40 ± 0.05
6.3
I206F
H6GGPP
16 ± 4
0.53 ± 0.14
5.0
L377H
H6GGPP
28 ± 11
0.94 ± 0.36
3.7
I206F/L377H
H6GGPP
29 ± 3
0.95 ± 0.09
2.6
G91H
H2GGPP
25 ± 4
0.83 ± 0.14
3.0
F219L
H4GGPP
23 ± 5
0.78 ± 0.15
3.0
Note: vapp, kapp, and t50 are the apparent rate, the apparent rate constant, and the time to
reach 50% maximal conversion from GGPP, respectively, for the products indicated.
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Figure S1, related to Figure 1. Binding of phosphatidylglycerol (PG) to SaGGR. (A)
Protein in cyan ribbons and FAD (C in yellow) and PG (C in green) in sticks (O in red, O
in blue, P in orange). 2FO–FC density around PG in blue mesh contoured at 1 !. (B) The
structure of PG in the model compared to 2,3-di-O-geranylgeranylglyceryl phosphate
(DGGGP), the native GGR substrate.
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OPO3PO 33-
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Figure S2, related to Figures 1, 2, and 4. The GGPP binding sites of SaGGR. (A) Of
the three GGPP molecules bound, only one (GGPP1) represents a catalytically relevant
binding site, with the "14 double bond positioned adjacent the N5 of FAD for reduction.
Electron density for the entire pyrophosphate moieties of GGPP2 and GGPP3 was
insufficient to model these head groups. Protein in cyan ribbons and FAD (C in yellow)
and GGPP (C in magenta) in sticks (O in red, O in blue, P in orange). 2FO–FC density
around GGPP molecules in blue mesh (1 !). (B) 2FO–FC omit density (blue mesh, 1 !) in
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GGPP-binding regions of the I206F SaGGR mutant. Although some weak density is
present, it is insufficient to include GGPP in the final model. Instead, the GGPP-binding
locations are shown based on the GGPP positions in the WT SaGGR structure. It should
be noted that strong density is observed near the phosphate head group of GGPP2. It is
possible that in the absence of GGPP2 a phosphate ion has bound to this position. (C) The
structure of GGPP and the proposed SaGGR-catalyzed stepwise reduction to H6GGPP.

Page 32 of 36!

A

1.2

Relative activity

1.0
0.8
0.6
0.4
0.2
0
20

B

30

40 50 60 70
Temperature (°C)

80

1.4

Relative activity

1.2
1.0
0.8
0.6
0.4
0.2
0

1

3

5
pH

7

9

Figure S3, related to Figure 3 and Table 2. Temperature and pH optima for WT
SaGGR. (A) The optimal temperature for the enzyme appeared at about 55°C, while (B)
the pH optimum was at about 5.5.
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Figure S4, related to Figures 3 and 4 and Table 2. Representative mass
spectrometry data from WT and mutant SaGGR enzymatic activity experiments,
determined by LC-TOF MS. The mass spectrum for the GGPP-only control without
added enzyme (bottom, red line) shows a single species representing unreacted GGPP
(parent peak a, m/z: 449.2; additional peaks observed in this spectrum represent GGPP
isotopic peaks [M+1], [M+2], etc.). In the enzymatic assay with WT SaGGR, GGPP is
rapidly consumed to form the singly-reduced intermediate H2GGPP (parent peak b, m/z:
451.2) before formation of the H4GGPP intermediate (parent peak c, m/z: 453.2).
Following a build-up of H4GGPP, further reduction to H6GGPP (parent peak d, m/z:
455.2) ensued, which is the final product. The fully reduced H8GGPP product (expected
m/z: 457.2) was not observed. Data for mutant SaGGR are also shown, depicting the
reduction of GGPP to H6GGPP for I206F, L377H, and I206F/L377H mutants. However,
GGPP reduction terminates at H2GGPP and H4GGPP for the G91H and F219L SaGGR
mutants, respectively.
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Table S1, related to Figures 3 and 4 and Table 2. Oligonucleotide primers used for
the generation of SaGGR mutants. Mutant codons are capitalized. The reverse primers
used contain the reverse complementary sequence of the forward primers below. The
I206F/L377H mutant was generated using the L377H oligonucleotide primer and the
I206F mutant sequence as the template.
Mutant

Forward primer (5'-)

I206F
L377H
G91H
F219L

gaggaccatgactacttgagaatattcTTTgatcaagagacatctccaggc
aagaagaagattataaaagaagaggatctgCATgaagcaagtgaaaaaggagatcttca
gatatgcagacagtatggacagtaaatCATgagggttttgaactaaatgccc
ccaggcggttattggtggtacCTGcctaaagggaagaacaaag
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